Skip to main content

Multiple Myeloma

Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Newly Diagnosed with measurable disease
  • No Prior Therapy

Dana Farber DFCI 14-508

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination for patients with Newly Diagnosed Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Must have had transplant due to high-risk features / Engraftment of neutrophils ANC greater than 1000 / Engraftment of platelets, PLT greater than 60 / Achievement of at least a PR prior to transplant / Absence of GI symptoms / Cord blood or haplo transplant not allowed

MM 42 SCRI Millennium

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD)

Criteria to qualify for study: Drug used in study:
  • New Diagnosed

MM 61 SCRI BMS CA204-154

A Phase 2 study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone (Erd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with MM.

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 75 CA209602 Bristol-Myers Squibb

An Open-Label Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory MM.

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 78 Celgene CC-4047-MM-014

A Phase 2, Multicenter, Multi-Cohort, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone or Pomalidomide in Comination with Low-Dose Dexamethasone and Dartumumab in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenadliomide-Based Therapy in the First or Second line Setting.

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 76 Celgene MED14736-MM-003

A Phase 2, Multicenter, Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (Durva) and Daratumumab (Dara) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma.

Newly Diagnosed

Criteria to qualify for this study: Drug used in study:
  • Must have at least 10% plasma cells in the marrow M-protein must be present in the serum and/or urine
  • Must have at least 1 myeloma-related organ dysfunction per CRAB criteria
  • Cannot have amyloid
  • PLT must be at least 50 unless marrow contains >50% plasma cells - then PLT must be at least 30
  • ANC must be at least 1000

Dana Farber DFCI 10-106

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age


Criteria to qualify for this study: Drug used in study:
  • Serum monoclonal protein ≥ 3 gm/dL and > 10% plasma cells in the bone marrow with a free light chain ratio outside the range of 0.125 to 8 OR Ratio or abnormal to normal bone marrow plasma cells ≥ 95% or at least one immunoglobulin level lower than the normal range
  • No evidence of CRAB criteria
  • Prior therapy for active Myeloma excluded

Dana Farber DFCI 14-338 CA-204-119

Phase II Trial of Combination of Elotuxzumab and Lenalidomide ± Dexamethasone in High-Risk Smoldering Multiple Myeloma


Criteria to qualify for this study: Drug used in study:
  • Must have relapsed or relapsed-and-refractory MM
  • Must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of proteasome inhibitor (same or separate regimens)
  • Must have measurable disease (serum M protein > 0.5g/dL or urine M protein > 200mg/24 hrs).

MM 65 ACE-MM-200

A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory
  • Serum M protein must be at least 1.0 g/dL
  • Urine M proteint must be at least 200 mg/24hr
  • Patients requiring anticoagulation with warfarin are excluded
  • ANC must be at least 1000
  • PLT must be at least 75
  • HGB must be at least 8

MM 51 SCRI PCYC-1119-CA

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibruitnib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma